OraSure Technologies (NASDAQ:OSUR) Upgraded to Hold at Wall Street Zen

OraSure Technologies (NASDAQ:OSUR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $3.00.

OraSure Technologies Stock Down 1.5%

OSUR stock opened at $3.97 on Friday. OraSure Technologies has a twelve month low of $2.08 and a twelve month high of $4.58. The company has a market cap of $273.33 million, a PE ratio of -3.82 and a beta of 1.01. The business’s 50-day simple moving average is $4.08 and its 200 day simple moving average is $3.33.

Insider Activity at OraSure Technologies

In other OraSure Technologies news, Director Steven Kyle Boyd bought 25,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the transaction, the director owned 113,462 shares in the company, valued at approximately $339,251.38. The trade was a 28.26% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC raised its holdings in shares of OraSure Technologies by 71.1% in the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock worth $6,781,000 after buying an additional 878,151 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of OraSure Technologies by 6.4% during the second quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier’s stock worth $5,611,000 after purchasing an additional 112,851 shares during the last quarter. Cannell Capital LLC grew its holdings in shares of OraSure Technologies by 33.7% during the second quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after purchasing an additional 470,536 shares during the last quarter. Kotler Kevin bought a new position in shares of OraSure Technologies in the fourth quarter valued at about $4,359,000. Finally, Bridgeway Capital Management LLC raised its holdings in shares of OraSure Technologies by 9.5% in the second quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock valued at $5,371,000 after buying an additional 154,985 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.